News Blog
Supporting the KidneyHealth COST Action
Post-Acute Sequelae of COVID-19 (PASC) in Hospitalized and Ambulatory Patients: A Comparative Study
BlaCaPOx advancing personalised treatment for non-muscle invasive bladder cancer (NMIBC)
We were selected as the recipients of the 2025 Metabolism Junior Faculty Award . Our paper, " Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics ", has been carefully evaluated and selected by a panel of experts in recognition of its scientific quality, innovation, and contribution to the field. On behalf of the journal Metabolism , the Editor-in-Chief, Dr. Christos Mantzoros, congratulated us and praised our outstanding work and contribution. Summary of the paper: Individuals at increased risk of type 2 diabetes have recently been classified into six prediabetes clusters, which stratify the risk of progression to diabetes and diabetes complications (low-risk clusters: 1, 2 and 4, high-risk clusters: 3, 5 and 6). Individuals in cluster 6 have an elevated risk of nephropathy and all-cause mortality despite delayed onset of diabetes. The urinary peptidome classifiers CKD273 (chronic kidney disease, CKD), HF2 (heart failure, HF) and CAD238 (coronary artery disease, CAD) are based on unique urinary peptide patterns and have shown potential for identifying individuals at risk for CKD and cardiovascular pathologies. This observational study investigates whether peptidome classifiers can differentiate complication risks across the prediabetes clusters and if a novel combination of peptides can distinguish high-risk from low-risk prediabetes clusters.
CephaMed Project Receives Funding from the German Federal Ministry for Research, Technology and Space
EU Cancer Mission Conference in Copenhagen, Denmark “Advancing cancer care: Focus on personalized treatment and innovation for all Europeans”
A new urine test detects Long COVID with over 95% accuracy. mosaiques diagnostics GmbH provides the key technology behind this diagnostic breakthrough.
AGI and Proteome Analysis: The Molecular Symbiosis of Diagnostics and Therapy
This study supports the feasibility of in silico predicting effects of therapeutic interventions on CKD progression. By identifying the most beneficial treatment combinations for individual patients, this approach paves the way for precision medicine in CKD. Detailed information can be found here .
In a podcast on the European Commission's CORDIS website, three researchers explain how their EU-funded research supports the goal of improving the treatment and diagnosis of prostate cancer. Among them is Prof. Dr. Dr. Harald Mischak who is focused on understanding the underlying molecular structures of certain types of cancers. His project, PCaProTreat, aims to identify the most appropriate therapeutic targets and drugs. Here is the LINK .